STOCK TITAN
  1. Home
  2. Sec-filings
  3. GALT
  4. [Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity

GALT CFO reports option exercises and same-day $6 share sales

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Galectin Therapeutics (GALT) Form 4: CFO Jack W. Callicutt exercised stock options for 600 shares and sold 600 shares on 11/05/2025 under a Rule 10b5-1 plan. Exercises occurred at $1.98, $1.11, and $1.72 per share, with sales at $6. Following these transactions, he held 7,614 shares directly.

Positive

  • None.

Negative

  • None.
Insider CALLICUTT JACK W
Role Chief Financial Officer
Sold 600 shs ($4K)
Type Security Shares Price Value
Exercise Stock option (right to buy) 200 $0.00 --
Exercise Stock option (right to buy) 200 $0.00 --
Exercise Stock option (right to buy) 200 $0.00 --
Exercise Common stock 200 $1.98 $396.00
Sale Common stock 200 $6.00 $1K
Exercise Common stock 200 $1.11 $222.00
Sale Common stock 200 $6.00 $1K
Exercise Common stock 200 $1.72 $344.00
Sale Common stock 200 $6.00 $1K
Holdings After Transaction: Stock option (right to buy) — 39,586 shares (Direct); Common stock — 7,814 shares (Direct)
Footnotes (1)
  1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023. The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024. The options vested as follows: 25% on each of June 30, 2024, December 31, 2024, and June 30, 2025, with 25% scheduled to vest on December 31, 2025.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CALLICUTT JACK W
(Last) (First) (Middle)
C/O GALECTIN THERAPEUTICS INC.
4960 PEACHTREE INDUSTRIAL BLVD., STE 240
(Street)
NORCROSS GA 30071
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 11/05/2025 M(1) 200 A $1.98 7,814 D
Common stock 11/05/2025 S(1) 200 D $6 7,614 D
Common stock 11/05/2025 M(1) 200 A $1.11 7,814 D
Common stock 11/05/2025 S(1) 200 D $6 7,614 D
Common stock 11/05/2025 M(1) 200 A $1.72 7,814 D
Common stock 11/05/2025 S(1) 200 D $6 7,614 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock option (right to buy) $1.98 11/05/2025 M(1) 200 06/30/0022(2) 01/24/2032 Common stock 200 $0 39,586 D
Stock option (right to buy) $1.11 11/05/2025 M(1) 200 06/30/2023(3) 01/26/2034 Common stock 200 $0 39,566 D
Stock option (right to buy) $1.72 11/05/2025 M(1) 200 06/30/2024(4) 01/22/2034 Common stock 200 $0 52,809 D
Explanation of Responses:
1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.
2. The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023.
3. The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024.
4. The options vested as follows: 25% on each of June 30, 2024, December 31, 2024, and June 30, 2025, with 25% scheduled to vest on December 31, 2025.
Jack W. Callicutt 11/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did GALT’s CFO report on this Form 4?

He exercised options for 600 shares and sold 600 shares on 11/05/2025.

Were the transactions under a Rule 10b5-1 plan?

Yes. The filing states they were made under a Rule 10b5-1 plan adopted on April 17, 2025.

At what prices were the options exercised and shares sold?

Options were exercised at $1.98, $1.11, and $1.72 per share; shares were sold at $6.

How many shares does the CFO own after the transactions?

He beneficially owns 7,614 shares directly after the reported transactions.

What is the officer’s role at Galectin Therapeutics (GALT)?

He is the company’s Chief Financial Officer.

What is the transaction date on the Form 4 for GALT?

The transactions took place on 11/05/2025.